explore -WSS

explore

author：Wikipedia 2025-10-02 16:18:44 - browse：1718

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： The inclusion problem at the heart of rehabilitation research

WSS

Printout prescription drug information shouldn’t go digital

TikTok, Instagram influencers need more rules for drug ads

Medicare drug price lawsuits could be good politics for Biden

Opioid cravings were reduced by anti

Mass General, Mayo Clinic look to monetize custom

Researchers tackle phage therapy hurdles for wider adoption

leisure time

explore

explore

The high cost of giving birth even with insurance

Reporting on presidential health from Reagan to Trump and Biden

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A new drug could help frostbite victims avoid its ravages

How one medical school became remarkably diverse

Obamacare plans could cover weight loss drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Cancer drug shortages should be causing more outrage

As AI regulations shape up, health tech startups beg for clarity

focus

FDA sets aggressive timeline for overhauling inspection procedures

Dog Aging Project founders on what lies ahead after losing funding

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Printout prescription drug information shouldn’t go digital

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Reporting on presidential health from Reagan to Trump and Biden

knowledge

leisure time

hotspot

hotspot